ADHD Lisdexamfetamine IND Melatonine Molindone ALL Brexucabtagene autoleucel IND Dasatinib G Obecabtagene autoleucel Ponatinib IND ALS Arimoclomol IND Sodium phenylbutyrate/tauroursodeoxycholic acid AML / MDS Azacitidine Cytarabine / daunorubicin (liposomaal) Decitabine/cedazuridine Eprenetapopt Glasdegib Imetelstat Iomab-B Venetoclax IND Aggressive non-Hodgkin’s lymphoma Axicabtagene ciloleucel IND Crizotinib IND Ibrutinib Mantle cell lymphoma (MCL), 1L. IND Extension of indication to include treatment with Imbruvica in combination with bendamustine and rituximab (BR) of adult patients with previously untreated mantle cell lymphoma (MCL) who are unsuitable for autologous stem cell transplantation Lisocabtagene maraleucel Loncastuximab tesirine Pirtobrutinib Polatuzumab vedotin IND Tafasitamab Zamtocabtagene autoleucel Zanubrutinib IND Antithrombotic medications Dabigatran G Proteïne C IND Ravulizumab IND Asthma Dupilumab IND Masitinib Tezepelumab Bacterial infections Ceftobiprole Ceftolozane / tazobactam IND Citric acid / lactic acid / potassium bitartrate IND Clindamycin Dalbavancine IND Delafloxacin IND Durlobactam / sulbactam Eravacycline SER 109 Tebipenem Bladder cancer Avelumab IND Durvalumab Neo-adjuvant durvalumab met chemotherapie en adjuvant durvalumab voor behandeling in patiënten met spier invasieve blaaskanker. IND Unresectable locally advanced or metastatic urothelial cancer in combination with tremelimumab and chemotherapy IND Enfortumab vedotin Inbakicept Nivolumab IND Bowel diseases Etrolizumab IND Filgotinib IND Mirikizumab Ozanimod IND Risankizumab IND Teduglutide IND Upadacitinib Rinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. IND Moderately to Severely Active Crohns disease IND Vedolizumab IND Brain cancer Autologous glioma tumor cell lysates Breast cancer Abemaciclib IND Amcenestrant Balixafortide Neratinib IND Olaparib IND Paclitaxel Palbociclib Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery. IND Patients with HR+/HER2- invasive early breast cancer in combination with standard adjuvant endocrine therapy. IND Pembrolizumab Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS ≥ 10 and who have not received prior chemotherapy for metastatic disease. IND KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early‑stage triple‑negative breast cancer at high risk of recurrence. IND Sacituzumab govitecan Tesetaxel Trastuzumab deruxtecan Enhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti HER2 based regimens. Extension of indication for Enhertu to include treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens. IND Patients with HER2 low, unresectable, and/or metastatic breast cancer previously treated with 1-2 prior lines of chemotherapy in the metastatic setting and has progressed on, and would no longer benefit from, endocrine therapy. IND Trastuzumab duocarmazine Tucatinib CLL Acalabrutinib Calquence as monotherapy is indicated for the treatment of adult patients with relapsed/refractory CLL (chronic lymphocytic leukemia). Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Duvelisib Ibrutinib IND Pirtobrutinib IND Ublituximab Zanubrutinib Extension of indication to include treatment of adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic leukaemia (SLL) IND Extension of indication to include treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one-prior anti-CD20-based therapy IND CML Asciminib COVID-19 APN01 Anakinra IND Baricitinib IND Casirivimab / imdevimab IND Casirivimab/imdevimab Molnupiravir PF-07321332 / ritonavir Regdanvimab IND Remdesivir Extension of indication to include adults who do not require invasive mechanical ventilation at start of treatment. • In adolescents (aged 12 to less than 18 years and weighing at least 40 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment). IND Treatment of paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) or other non-invasive ventilation at start of treatment IND Sotrovimab Tixagevimab / cilgavimab The prevention of COVID-19 in adults. Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen. IND Tocilizumab IND Cervical cancer Cemiplimab IND Durvalumab IND Lifileucel Colon cancer Nivolumab IND Tegafur / gimeracil / oteracil IND Cystic fibrosis Elexacaftor / tezacaftor / ivacaftor Kaftrio is indicated in a combination regimen with ivacaftor 150mg tablets for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene IND Ivacaftor IND Dementia Aducanumab Depression Bupropion/dextromethorphan Esketamine IND Zuranolone Diabetes Bexagliflozine Dapagliflozine IND Dasiglucagon Exenatide IND Finerenon Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. Extension of indication to include the treatment of chronic kidney disease (CKD) and for the prevention of cardiovascular (CV) events in adults with CKD (regardless of the stage of albuminuria) associated with type 2 diabetes IND Insulin lispro G Polyethylene glycol loxenatide Sotagliflozine IND Teplizumab Tirzepatide Duchenne Golodirsen Vamorolone Epilepsy Brivaracetam IND Cannabidiol IND Cenobamaat Fenfluramine IND Ganaxolone Lacosamide IND Eye disorders Aflibercept IND Avacincaptad pegol Brolucizumab IND Faricimab Treatment of neovascular (wet) age-related macular degeneration (nAMD). Treatment of visual impairment due to diabetic macular oedema (DME). Lenadogene nolparvovec Pegcetacoplan IND Perfluorohexyloctane Phentolamine Ranibizumab Wet age-related macular degeneration (AMD). BS Wet age-related macular degeneration (AMD). BS Treatment of neovascular age-related macular degeneration (AMD) Reproxalap Sepofarsen Timrepigene emparvovec Fungal infections Ibrexafungerp IND Oteseconazole Posaconazol Extension of indication to include primary treatment of invasive aspergillosis in adults and adolescents from 13 years of age for Noxafil gastroresistant tablet and concentrate for solution for infusion. IND Extension of indication to include primary treatment of invasive aspergillosis in paediatric patients from 2 years of age weighing more than 40kg and adults for Noxafil gastroresistant tablet and concentrate for solution for infusion. Noxafil gastro-resistant tablets and solution are indicated for use in the treatment of the following fungal infections: Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products. IND Rezafungin HIV Atazanavir / cobicistat Doravirine / lamivudine / tenofovirdisoproxil IND Fostemsavir Lenacapavir Raltegravir BS Head and neck cancer Pembrolizumab IND Tislelizumab IND Headache Atogepant Dihydroergotamine Eptinezumab Lasmiditan Meloxicam / rizatriptan Rimegepant Hemostasis promoting medication Emicizumab IND Eptacog alfa (activated) BS Eptacog beta (activated) Etranacogene dezaparvovec FLT180a Valoctocogene roxaparvovec Indolent non-Hodgkin’s lymphoma Axicabtagene ciloleucel IND Copanlisib Hypericin Lacutamab Mosunetuzumab Parsaclisib Umbralisib Infectious diseases other Baloxavir marboxil IND Fluticasone propionate Kidney cancer Avelumab IND Cabozantinib IND Lenvatinib IND Pembrolizumab Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC). IND Keytruda as monotherapy is indicated for the adjuvant treatment of adults with renal cell carcinoma at increased risk of recurrence following nephrectomy or following nephrectomy and resection of metastatic lesions. IND Tivozanib IND Lipid-lowering medications Bempedoic acid Evinacumab Evolocumab IND Inclisiran Liver cancer Durvalumab Durvalumab (+/- bevacizumab) in combinatie met TACE in patiënten met locoregionale HCC. IND Extension of indication to include IMFINZI in combination with tremelimumab for the treatment of adults with unresectable hepatocellular carcinoma (uHCC). IND Lenvatinib IND Pembrolizumab IND Pemigatinib Tremelimumab IND Liver diseases Maralixibat IND Obeticholic acid Seladelpar Lung cancer Adagrasib Amivantamab Atezolizumab Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells (TC) and who do not have EGFR mutant or ALK‑positive NSCLC IND Extension of indication to include adjuvant treatment of non-small cell lung cancer (NSCLC) following resection and platinum-based chemotherapy for adult patients whose tumours have PD-L1 expression on ≥ 1% of tumour cells (TC) for Tecentriq as monotherapy IND Avelumab IND Capmatinib Cemiplimab Libtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have locally advanced NSCLC who are not candidates for definitive chemoradiation, or metastatic NSCLC. IND Extension of indication to include LIBTAYO in combination with platinum‐based chemotherapy for the first-line treatment of adult patients with locally advanced NSCLC who are not candidates for definitive chemoradiation or metastatic NSCLC with no EGFR, ALK or ROS1 aberrations, independen of PD-L1 expression. IND Durvalumab Extension of indication to include first-line treatment, with Imfinzi in combination with tremelimumab and platinum-based chemotherapy, of adults with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. IND Non-small cell lung cancer (NSCLC) stage IV, in combination with chemo, 1L. IND 1L advanced NSCLC IND Completely resected NSCLC IND Lokaal gevorderd, niet-resectabel NSCLC (stadium III) IND Limited stage small cell lung cancer (LS-SCLC) following concurrent platinum-based chemotherapy and radiation therapy in combination with Tremelimumab. IND Ensartinib Lenvatinib IND Lorlatinib IND Lurbinectedin Mobocertinib Nivolumab IND OSE-2101 Osimertinib IND Pembrolizumab IND Pralsetinib Selpercatinib IND Sintilimab Sotorasib Tepotinib Tislelizumab Toripalimab Trastuzumab deruxtecan IND Tremelimumab Trilaciclib Lung diseases other Ambrisentan IND Benralizumab IND Gefapixant Mepolizumab Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) to Nucala IND Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). Pirfenidone IND Mesothelioma Nivolumab IND Metabolic diseases Arimoclomol Autologous CD34+ cell enriched population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A gene Avalglucosidase alfa Bardoxolone Methyl Betaine G Cipaglucosidase alfa / miglustat Elamipretide Fexapotide Fezolinetant Fosdenopterin Hydrocortison Leriglitazone Levoketoconazole Liraglutide IND Lonafarnib Migalastat IND Octreotide Olenasufligene relduparvovec Olipudase alfa Palovarotene Pegunigalsidase alfa Reloxaliase Sapropterin G Somatrogon Sparsentan Multiple Myeloma Belantamab mafodotin IND Carfilzomib IND Ciltacabtagene autoleucel Daratumumab Extension of indication to extend the existing therapeutic indication for daratumumab in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). IND Extension of indication to extend the existing therapeutic indication for daratumumab in combination with lenalidomide and dexamethasone (Rd) for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT). IND Darzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. IND In combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide-refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy. IND Multipel myeloom frontline behandeling in combinatie met VRd voor patiënten die niet in aanmerking komen voor een ASCT. IND Smouldering multipel myeloom. IND Elranatamab Idecabtagene vicleucel Isatuximab Sarclisa is indicated in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. IND In Combination With Bortezomib, Lenalidomide and Dexamethasone (Isa VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. IND Ixazomib IND Melphalan flufenamide IND Pomalidomide IND Selinexor IND Teclistimab Thalidomide G Venetoclax IND Zevorcabtagene autoleucel Multiple sclerosis Dimethyl fumarate Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Diroximel fumarate Ofatumumab Teriflunomide Aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis. IND Volwassenen met 'relapsing remitting' multipele sclerose (RRMS). G Ublituximab Muscular diseases other Amifampridine G Bidridistrogene xeboparvovec Daxibotulinumtoxine A Deoxythymidine/deoxycytidine Di-deuterated ethyl linoleate Efgartigimod Ravulizumab IND Sugammadex G Myeloproliferative disorders Momelotinib Navitoclax Ropeginterferon alfa-2b Neuroendocrine cancer Selumetinib Surufatinib Neurological disorders other Cannabidiol gel/intradermaal Clazosentan Eculizumab IND Eladocagene exuparvovec Inebilizumab Remimazolam Rozanolixizumab Satralizumab Tiratricol Vutrisiran Zilucoplan Oncology other Afamitresgene autoleucel Dostarlimab Durvalumab IND Efbemalenograstim alfa Erdafitinib Futibatinib Glucarpidase Infigratinib Ivosidenib IND Jodium (131I) omburtamab Lenvatinib Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation IND Advanced or Recurrent Endometrial Cancer (1L) in combination with pembrolizumab. IND Lipegfilgrastim IND NY-ESO-1 autologous engineered TCR-T cells Nivolumab Opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy IND Extension of indication to include in combination with fluoropyrimidineand platinum-based combination chemotherapy the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OSCC) for OPDIVO. IND Pembrolizumab Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation. IND Keytruda, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a CPS ≥ 1. IND Keytruda, in combination with platinum and fluoropyrimidine based chemotherapy, is indicated for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastroesophageal junction adenocarcinoma in adults whose tumours express PD‑L1 with a CPS ≥ 10. IND Keytruda as monotherapy is indicated for the treatment of the following MSI‑H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine‑based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy. IND Selinexor IND Sodium thiosulfate Tebentafusp Other chronic immune diseases Adrenaline Arachis hypogaea (pinda) allergenen (pleister) Avacopan Avapritinib IND Baricitinib Systemic lupus erythematosus IND Extension of indication to include treatment of severe alopecia areata in adult patients for Olumiant. IND Berotralstat Budesonide modified released capsule IND Canakinumab IND Coacillium topical Dupilumab IND FCR 001 Icatibant G Mavorixafor OTL 103 RP-L201 Sizavaleucel Sutimlimab Voclosporin Vonoprazan Other hematology Eltrombopag IND Zanubrutinib Other medication for cardiovascular diseases Allogenic immunomodulatory progenitor cells Angiotensin II Apabetalon Dapagliflozine IND Emiplacel Empagliflozine IND Etripamil Fibrinogen / Thrombin IND Icosapent ethyl Macitentan IND Macitentan / tadalafil Mavacamten Omecamtiv mecarbil Rexlemestrocel-L Rilonacept Sotagliflozine IND Tadalafil IND Tafamidis IND Udenafil Vericiguat Other metabolism and Endocrinology Abaloparatide Burosumab IND Corifollitropin alfa IND Drospirenon / estetrol, monohydraat Ospemifene Semaglutide Setmelanotide IND Other non-oncological hematological medications Crizanlizumab Daprodustat Eculizumab BS Efgartigimod Eptacog alfa IND Exagamglogene autotemcel Horse anti-human T lymphocyte immunoglobulin Luspatercept IND Mepolizumab IND Mitapivat Pegcetacoplan RP-L102 Ravulizumab Behandeling van volwassen en pediatrische patiënten met een lichaamsgewicht van 10 kg of meer met paroxismale nachtelijke hemoglobinurie (PNH): - bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit. - bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab Uitbreiding van de behandeling naar pediatrische patiënten met een lichaamsgewicht van 10kg of meer met paroxismale nachtelijke hemoglobinurie (PNH):- bij patiënten met hemolyse met klinische symptomen die wijzen op een hoge ziekteactiviteit.- bij patiënten die klinisch stabiel zijn nadat ze ten minste de afgelopen 6 maanden behandeld zijn met eculizumab. IND UM171 Vadadustat Voxelotor Other psychiatry Dexmedetomidine Ovarian cancer Dostarlimab IND Mirvetuximab soravtansine Pain Bupivacaine extended release IND Buprenorphine IND Fasinumab Lidocaïne SDN037 Parasitic infections Lotilaner Prostate cancer Abiraterone Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT). - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is. - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. G Geïndiceerd met prednison of prednisolon voor: - de behandeling van nieuw gediagnosticeerde hoog-risico gemetastaseerde hormoongevoelige prostaatkanker (mHSPC) bij volwassen mannen, in combinatie met androgeendeprivatietherapie (ADT); - de behandeling van gemetastaseerde castratieresistente prostaatkanker (mCRPC) bij volwassen mannen die asymptomatisch of licht symptomatisch zijn na falen van androgeendeprivatietherapie en voor wie behandeling met chemotherapie nog niet klinisch geïndiceerd is; - de behandeling van mCRPC bij volwassen mannen bij wie de ziekte progressief was tijdens of na een chemotherapieschema op basis van docetaxel. G Darolutamide Nubeqa is indicated for the treatment of adult men with non-metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Adult men with metastatic hormone senstive prostate cancer (mHSPC) in combination with docetaxel en ADT. IND Degarelix IND Leuprolide mesylate Lutetium (177lu) vipivotide tetraxetan Masitinib Niraparib / abiraterone Olaparib Treatment in combination with abiraterone acetate in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) who have not received prior chemotherapy or new hormonal agents (NHAs) for metastatic castration-resistant prostate cancer (mCRPC) (first-line setting). IND treatment of adults with metastatic castration resistant prostate cancer (mCRPC), with Lynparza in combination with abiraterone and prednisone or prednisolone IND Pembrolizumab IND Relugolix Rheumatism Anifrolumab Cyclobenzaprine hydrochloride Risankizumab IND Sarilumab IND Secukinumab Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. IND Extension of indication to include treatment of Juvenile Idiopathic Arthritis (Enthesitis Related Arthritis and Juvenile Psoriatic Arthritis) in patients 2 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. IND Tofacitinib IND Upadacitinib IND SMA Risdiplam 5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies. Extension of indication to include treatment of patients below 2 months of age. IND Schizophrenia, psychosis, bipolar disorder Lumateperone Skin cancer Darleukin fibromun Lenvatinib IND Pembrolizumab 1L treatment with pembrolizumab for advanced melanoma, in combination with lenvatinib. IND Extension of indication to include the adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB, Stage IIC or stage III melanoma and to include the treatment of adolescents aged 12 years and older with advanced melanoma for Keytruda IND Relatlimab Skin diseases Abrocitinib Beremagene geperpavec Berkenschorsextract Deucravacitinib Difelikefalin Dupilumab Dupixent is geïndiceerd bij kinderen van 6 maanden tot 6 jaar met ernstige atopische dermatitis die in aanmerking komen voor systemische behandeling. IND Dupixent is geïndiceerd bij volwassenen voor de behandeling van Prurigo Nodularis die onvoldoende onder controle zijn met topische behandelingen, of wanneer deze behandelingen niet gepast zijn. IND Lebrikizumab Ligelizumab Regenerative Skin Tissue Roflumilast topical Ruxolitinib phosphate Secukinumab IND Spesolimab Tapinarof Adult Plaque Psoriasis Atopische dermatitis Tirbanibulin Tralokinumab IND Sleep disorders Daridorexant JZP-258 Natriumoxybaat controlled release Pitolisant Stem cell transplants Brexucabtagene autoleucel Inolimomab Motixafortide Omidubicel Ruxolitinib IND Tabelecleucel Tisagenlecleucel-T IND Treosulfan IND Stomach cancer Nivolumab IND Ripretinib Trastuzumab deruxtecan IND Zolbetuximab Thyroid cancer Cabozantinib IND Pralsetinib Gavreto is indicated for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy following prior treatment with Tyrosine Kinase inhibitors and not previously treated with a RET inhibitor. Gavreto is indicated for the treatment of adults and pediatric patients 12 years of age and older with locally advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy following prior treatment with Tyrosine kinase inhibitors and not previously treated with a RET inhibitor. IND Selpercatinib 1L treatment advanced or metastatic RET fusion-positive thyroid cancer (TC) IND 1L treatment of adults and children >12 years of age with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). IND Unknown Axicabtagene ciloleucel IND Dapagliflozine IND Diazoxide choline (controlled-release tablet) Empagliflozine IND Levonorgestrel G Linzagolix Lonapegsomatropin Lumasiran Mirabegron IND Olopatadine / mometasone Osilodrostat Pirfenidone G Relugolix IND Relugolix / estradiol / norethisteronen Setmelanotide Sirolimus IND Sofpironium bromide Vosoritide Viral infections other Bizalimogene ralaplasmid Bulevirtide Elbasvir / grazoprevir IND Glecaprevir / pibrentasvir IND Lonafarnib IND Maribavir Nirsevimab Remdesivir IND Sofosbuvir / velpatasvir IND Sofosbuvir / velpatasvir / voxilaprevi IND Tecovirimat